MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573993 | Name: MVN 38083
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MVN 38083, also known as N-desmethyl Ivabradine (hydrochloride) is an active metabolite of ivabradine. Ivabradine is metabolized by the cytochrome P450 (CYP) isoform CYP3A4. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

MVN 38083
MVN 38083
CAS#1246638-08-3

Theoretical Analysis

MedKoo Cat#: 573993

Name: MVN 38083

CAS#: 1246638-08-3

Chemical Formula: C26H35ClN2O5

Exact Mass: 490.2234

Molecular Weight: 491.03

Elemental Analysis: C, 63.60; H, 7.18; Cl, 7.22; N, 5.71; O, 16.29

Price and Availability

Size Price Availability Quantity
5mg USD 460.00 2 weeks
10mg USD 850.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
N-desmethyl Ivabradine (hydrochloride); MVN 38083; MVN-38083; MVN38083
IUPAC/Chemical Name
3-[3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]amino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one, monohydrochloride
InChi Key
MIIIKWNQFDQJGS-VEIFNGETSA-N
InChi Code
InChI=1S/C26H34N2O5.ClH/c1-30-22-11-17-6-9-28(26(29)14-18(17)12-23(22)31-2)8-5-7-27-16-20-10-19-13-24(32-3)25(33-4)15-21(19)20;/h11-13,15,20,27H,5-10,14,16H2,1-4H3;1H/t20-;/m1./s1
SMILES Code
COC(C(OC)=C1)=CC2=C1[C@H](C2)CNCCCN3CCC(C=C(OC)C(OC)=C4)=C4CC3=O.Cl
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
N-Demethyl Ivabradine Hcl is a metabolite of Ivabradine, which is a specific inhibitor of the funny channel.
In vitro activity:
In vitro whole-cell patch-clamp and in vivo extracellular recordings showed that direct application of ivabradine to the spinal cord decreases the mean miniature excitatory postsynaptic currents' frequency (13 rats; P < 0.01), and direct and peripheral application of ivabradine suppresses the spinal response to mechanical stimulation-evoked firing (8 rats/group, P < 0.01). Moreover, ivabradine reduces the amplitudes of monosynaptic excitatory postsynaptic currents evoked by Aδ-fiber and C-fiber stimulation (6 rats; P < 0.01) and induces a stronger inhibition of those evoked by C-fiber stimulation. Reference: Pain. 2022 Jul 1;163(7):1356-1369. https://pubmed.ncbi.nlm.nih.gov/35708467/
In vivo activity:
Twenty-eight Wistar rats were divided into non-diseased controls, rats treated with ivabradine, rats treated with isoproterenol, and rats treated with isoproterenol plus ivabradine. Ivabradine reduced HR (by 15%), partly prevented SBP decline (by 10%) and site-specifically mitigated kidney fibrosis by decreasing type I collagen volume in all three sites investigated (by 69, 58, and 67%, respectively) and the ratio of type I collagen-to-type III collagen in glomerular and vascular/perivascular sites (by 79 and 73%, respectively). Reference: Gen Physiol Biophys. 2023 Mar;42(2):209-215. https://pubmed.ncbi.nlm.nih.gov/36896950/
Solvent mg/mL mM
Solubility
DMF 25.0 50.91
DMSO 43.3 88.25
Ethanol 1.0 2.04
PBS (pH 7.2) 10.0 20.37
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 491.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ohashi N, Uta D, Ohashi M, Baba H. Analgesic effect of ivabradine against inflammatory pain mediated by hyperpolarization-activated cyclic nucleotide-gated cation channels expressed on primary afferent terminals in the spinal dorsal horn. Pain. 2022 Jul 1;163(7):1356-1369. doi: 10.1097/j.pain.0000000000002523. Epub 2021 Oct 23. PMID: 35708467. 2. Hackl B, Lukacs P, Ebner J, Pesti K, Haechl N, Földi MC, Lilliu E, Schicker K, Kubista H, Stary-Weinzinger A, Hilber K, Mike A, Todt H, Koenig X. The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels. Front Pharmacol. 2022 May 2;13:809802. doi: 10.3389/fphar.2022.809802. PMID: 35586063; PMCID: PMC9108390. 3. Baka T, Stanko P, Repova K, Aziriova S, Krajcirovicova K, Barta A, Zorad S, Simko F. Ivabradine curbs isoproterenol-induced kidney fibrosis. Gen Physiol Biophys. 2023 Mar;42(2):209-215. doi: 10.4149/gpb_2022057. PMID: 36896950. 4. Woodman R, Student J, Miller C, Lockette W. Ivabradine-Induced Bradycardia Is Accompanied By Reduced Stress-Related Anxiety. Am J Hypertens. 2023 Feb 22:hpad019. doi: 10.1093/ajh/hpad019. Epub ahead of print. PMID: 36812223.
In vitro protocol:
1. Ohashi N, Uta D, Ohashi M, Baba H. Analgesic effect of ivabradine against inflammatory pain mediated by hyperpolarization-activated cyclic nucleotide-gated cation channels expressed on primary afferent terminals in the spinal dorsal horn. Pain. 2022 Jul 1;163(7):1356-1369. doi: 10.1097/j.pain.0000000000002523. Epub 2021 Oct 23. PMID: 35708467. 2. Hackl B, Lukacs P, Ebner J, Pesti K, Haechl N, Földi MC, Lilliu E, Schicker K, Kubista H, Stary-Weinzinger A, Hilber K, Mike A, Todt H, Koenig X. The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels. Front Pharmacol. 2022 May 2;13:809802. doi: 10.3389/fphar.2022.809802. PMID: 35586063; PMCID: PMC9108390.
In vivo protocol:
1. Baka T, Stanko P, Repova K, Aziriova S, Krajcirovicova K, Barta A, Zorad S, Simko F. Ivabradine curbs isoproterenol-induced kidney fibrosis. Gen Physiol Biophys. 2023 Mar;42(2):209-215. doi: 10.4149/gpb_2022057. PMID: 36896950. 2. Woodman R, Student J, Miller C, Lockette W. Ivabradine-Induced Bradycardia Is Accompanied By Reduced Stress-Related Anxiety. Am J Hypertens. 2023 Feb 22:hpad019. doi: 10.1093/ajh/hpad019. Epub ahead of print. PMID: 36812223.
1. Rosa, G.M., Ferrero, S., Ghione, P., et al. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin. Drug Metab. Toxicol. 10(2), 279-291 (2014).